Barry Vaught, MD
Neurology · Crab Orchard, WVNPI 1194770339
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,208,512 of the $1,441,710 with a category attached, or 83.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.7%. Among neurology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,281 payments — averaging $439.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$270K
- Neurocrine Biosciences, Inc.$210K
- Argenx US, Inc.$208K
- Teva Pharmaceuticals USA, Inc.$168K
- Biogen$94K
- Amgen$55K
- plus $436K from 54 others
Across 627 payments — averaging $2522.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$543K
- Amgen$429K
- UCB SA$289K
- Teva Pharmaceuticals USA, Inc.$101K
- Jazz Pharmaceuticals Inc.$49K
- Bristol Myers Squibb$44K
- plus $127K from 7 others
What the payments were for
- Consulting fees$94,5697%
- Speaking & faculty fees$1,208,51284%
- Grants$440%
- Travel & lodging$80,5786%
- Food & beverage$56,4334%
- Education$1,5730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$234,372
- INGREZZA$205,492
- VYVGART$140,046
- QULIPTA$87,221
- Vumerity$63,878
- VYVGART HYTRULO$62,931
- AUSTEDO$58,881
- NURTEC ODT$58,595
- Austedo XR$54,892
- AIMOVIG$54,566
- AJOVY$50,332
- Leqembi$39,073
- VALTOCO$36,940
- EMGALITY$34,513
- VYEPTI$34,211
- Mavenclad$25,283
- NUEDEXTA$22,861
- Rystiggo$17,503
- TYSABRI$16,602
- INBRIJA$16,534
How this compares
$1,441,710 in reported general payments places this provider in the 95th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 177 | $843,460 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 35 | $709,920 |
| Austedo XrDeutetrabenazine | 95 | $629,724 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 67 | $629,225 |
| AustedoDeutetrabenazine | 65 | $542,178 |
| Nurtec OdtRimegepant Sulfate | 293 | $401,206 |
| EpidiolexCannabidiol (Cbd) | 22 | $270,127 |
| ZeposiaOzanimod Hydrochloride | 30 | $261,794 |
| Kesimpta PenOfatumumab | 25 | $258,225 |
| IngrezzaValbenazine Tosylate | 31 | $241,094 |
| QuliptaAtogepant | 192 | $236,177 |
| MayzentSiponimod | 24 | $235,516 |
| UbrelvyUbrogepant | 156 | $220,601 |
| AptiomEslicarbazepine Acetate | 93 | $176,228 |
| Teriflunomide | 104 | $172,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $168,371 | $1,171,902160 claims |
| Acadia Pharmaceuticals IncNuplazid | $5,437 | $843,460177 claims |
| CSL BehringPrivigen | $207 | $629,22567 claims |
| AbbVieQulipta, Ubrelvy, Botox | $269,919 | $522,897401 claims |
| PfizerNurtec Odt | $1,415 | $401,206293 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $8,486 | $261,79430 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $209,557 | $241,09431 claims |
| NovartisMayzent | $2,702 | $235,51624 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $479 | $176,22893 claims |
| UCB, Inc.Briviact, Nayzilam | $25,902 | $168,155125 claims |
| MDD US Operations, LLCGocovri | $643 | $96,74923 claims |
| SK Life Science, Inc.Xcopri | $9,340 | $88,13067 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in West Virginia.
Other neurology in Crab Orchard
- Paul FergusonHuntington$649K
- Umer NajibMorgantown$246K
- Muhammed Nasher-AlneamCharleston$73K
- Robert LewisHurricane$73K
- Lauren SeebergerCharleston$72K
- Cheryl SmithMorgantown$68K
- Mouhannad AzzouzMorgantown$40K
- Gregory MathewsCharleston$30K
- Ronald BareboHuntington$28K
- Adnan AlghadbanBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.